See our roundup of today's AIM risers - see the full LSE winners & losers board here.
Amerisur Resources rises 20% to 12p a share
Amerisur Resources (AMER) signed a $93.25m farm-out with Occidental Andina, an affiliate of an international oil and gas exploration and production company.
The farm out is for its Putumayo-9, Terecay, Tacacho and Mecaya blocks in the Putumayo region, southern Colombia, which extend over 1.4 million acres and have prospective resources of 656 MMBO.
John Wardle, CEO of Amerisur said: "The farm out recognises the significant value we have created during our growth phase over the last few years and this transaction will now amply fund, widen and bring forward our exploration programmes in the Put-9, Tacacho, Terecay and Mecaya properties, which we and our new partner believe to hold very substantial resource potential.
Read more here & follow AMER here:
Mobile Streams rises 33% to 1p a share
Mobile Streams (MOS) welcomed its 6 millionth user.
Featuring over 300 titles including racing, puzzle and endless runner games, the HTML5 games service has reached over 6 million subscribers since launch in recent months.
Simon Buckingham, CEO of Mobile Streams said: "We are very happy with the performance of our HTML5 games store since launching in India in 2018. We are very appreciative of the support and expertise CoolGames have provided and expect the partnership to flourish in the future.
Read more here & follow MOS here:
PowerHouse Energy rises 14% to 0.525p a share
PowerHouse Energy (PHE) has been gathering momentum following Align Research releasing a conviction buy rating for the company.
Pioneering waste-to-hydrogen tech “now on the cusp of commercialisation & creating significant shareholder value” according to the report.
The DCF analysis suggests an NPV(20) of £47.4 million, or 2.45p per share, some 6 times the current share price.
Read more here & follow PHE here:
ImmuPharma Rises over 7%
ImmuPharma (IMM) rose 7.5% this morning to 13.17p a share
The company is a specialist drug discovery and development company headquartered in London with research operations in France and Switzerland.
The company is focused on achieving the full regulatory approval of LupuzorTM which it believes has the potential to be a groundbreaking drug for lupus patients with “blockbuster potential in commercial terms”.
Read more here & follow IMM here:
See all today's AIM Risers here
